May 3rd 2024
Administering high-intensity focused ultrasound could be a noninferior treatment option for patients with localized prostate cancer, according to a prospective trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Progress in Prostate Cancer Care: Highlights From a Decade of Innovation
September 27th 2022Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with prostate cancer over the past decade.
Read More
Pembrolizumab and Olaparib Combo Did Not Significantly Improve PFS and OS in mCRPC
September 12th 2022No statistically significant improvement in radiographic progression-free survival and overall survival was seen with pembrolizumab plus olaparib in metastatic castration-resistant prostate cancer.
Read More
2-Year ADT Plus Radiotherapy Following Surgery Improves MFS in Prostate Cancer
September 12th 2022The addition of 2 years of androgen-deprivation therapy to radiotherapy after radical prostatectomy improved metastasis-free survival and time to salvage therapy in patients with prostate cancer.
Read More
First-line Olaparib Triplet Improves Outcomes in mCRPC
September 11th 2022Signs of an overall survival benefit were seen with a regimen of olaparib plus abiraterone acetate and prednisone or prednisolone as a first-line therapy for patients with metastatic castration-resistant prostate cancer, according to updated data from the phase 3 PROpel trial.
Read More
Enzalutamide/Abiraterone Acetate/Prednisolone Combo in mHSPC Not Recommended
September 11th 2022Androgen deprivation therapy plus abiraterone acetate and prednisolone resulted in a clinically meaningful overall survival benefit, but this in combination with enzalutamide fell short in patients with metastatic hormone-sensitive prostate cancer.
Read More
KEYNOTE-365 2-Year Update Shows Benefit of Pembrolizumab Plus Abiraterone in mCRPC
September 11th 2022An updated analysis of the KEYNOTE-365 study of pembrolizumab plus abiraterone showed that patients with chemotherapy-naive metastatic castration-resistant prostate cancer had prostate-specific antigen responses.
Read More
Treating mCSPC with Anti-Androgen Therapy and Monitoring for Progression
August 17th 2022During a live virtual event, Roby A. Thomas, MD, discussed the tolerability of androgen receptor therapy and personal experiences with treatment of patients with metastatic castration-sensitive prostate cancer. This is the second of 2 articles based on this event.
Read More
KEYNOTE-921 Trial of Pembrolizumab and Chemo Fails to Improve Survival in mCRPC
August 10th 2022The phase 3 KEYNOTE-921 trial did not meet its coprimary end points of overall survival and radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
Read More